Unveiling metabolic remodeling in mucopolysaccharidosis type III through integrative metabolomics and pathway analysis

Table 2 Statistical and discriminant metrics of the selected annotated features

HMDB	Putative annotation	MPSIIIA			MPSIIIB			MPSIIIC			MPSIIID
HMDB	Putative annotation	FDR	AUC	VIP	FDR	AUC	VIP	FDR	AUC	VIP	FDR	AUC	VIP
HMDB01238	N-Acetylserotonin	2.28E−03	0.83	1.21	6.05E−01	0.83	0.93	8.61E−01	0.61	0.99	9.70E−01	0.54	0.35
HMDB12267	N-Succinyl-l,l-2,6-diaminopimelate	3.88E−01	0.60	0.56	7.44E−01	0.63	0.64	9.06E−03	0.73	1.29	6.56E−01	0.69	0.05
HMDB33752	3-2-Hydroxyphenyl-propanoic acid	1.76E−02	0.76	1.53	5.30E−01	0.77	1.76	3.31E−01	0.66	0.93	7.56E−01	0.62	0.22
HMDB10347	Octanoylglucuronide	6.75E−01	0.58	0.69	3.86E−01	0.72	1.95	8.54E−01	0.64	0.51	2.57E−02	0.79	1.90

FDR false discovery rate, AUC area under the curve, VIP variable importance in projection
Significant features are highlighted in italics for control and each disease comparison (false discovery rate FDR = 5%)

ISSN: 1479-5876